In Buenos Aires, Argentina, cousins Llamazares and D'Alvia founded Stämm, a startup based on the idea of decentralizing biomanufacturing processes and downsizing biotech facilities. After raising its seed and series A rounds, and while finalizing its series B round in early 2024, the startup reached a key milestone as it successfully tested the core module of its cutting-edge platform, Stämm's Bioprocessor. The founders had demonstrated their ability to assemble a team of top-tier scientists, spearhead multidisciplinary R&D projects, and secure funding. As Stämm prepared to transition to product launch, they faced key challenges to craft the startup's business model and growth strategy, as well as to choose the optimal model for scaling their technological platform.